Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Bio-Targeting Therapeutics Technology Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being examined by 1 distinct examiner, Arthur S Leonard, in 1 distinct art unit. Arthur S Leonard is the busiest examiner, with 1 pending office action. The portfolio's current activity is highly centralized, with all pending work residing with a single examiner. This suggests a narrow and specific focus for the company's current biotechnology patent prosecution efforts.
The involvement of 1 distinct examiner and 1 distinct art unit means that the 1 pending office action will be reviewed according to a consistent set of standards. Because Arthur S Leonard is the only examiner involved, his specific history and the practices of the 1 distinct art unit are critical for the company's strategy. This centralized structure in the Biotechnology & Pharmaceuticals sector allows for a streamlined management process. Practitioners can focus their efforts on a single point of contact at the patent office to resolve the company's active matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17700991 | MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS | LEONARD, ARTHUR S | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17700991 | MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS | LEONARD, ARTHUR S | 1631 | §103§112DP | Non-Final OA | — | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Bio-Targeting Therapeutics Technology Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Arthur S Leonard has the most, with 1 of Beijing Bio-Targeting Therapeutics Technology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
